Abstract
It has been demonstrated that 5-HT1A receptors play an important role in the pathophysiology of schizophrenia. Because Gastrodia elata Bl (GE) modulates the serotonergic system, we examined whether GE could affect phencyclidine (PCP)-induced abnormal behavior in mice. Repeated treatment with PCP increased immobility time, while it decreased social interaction time and recognition memory. PCP-induced abnormal behaviors were significantly attenuated by GE, and these effects were comparable to those of 8-OH-DPAT, a 5-HT1A receptor agonist. Furthermore, GE-mediated effects were counteracted by WAY 100635, a 5-HT1A receptor antagonist. Our results suggest that the antipsychotic effects of GE are, at least in part, mediated via activation of 5-HT1A in mice.
Keywords: Gastrodia elata Bl, phencyclidine, schizophrenia, 5-HT1A receptors, chronic, devastating, anxiolytic, anti-depressant, anti-convulsant, anti-oxidant, anti-depressant effects
Current Neuropharmacology
Title: Effects of Gastrodia Elata Bl on Phencyclidine-Induced Schizophrenia-Like Psychosis in Mice
Volume: 9 Issue: 1
Author(s): E.-J. Shin, J.-M. Kim, X.-K. T. Nguyen, T.-T. L. Nguyen, S. Y. Lee, J.-H. Jung, M. J. Kim, W. K. Whang, K. Yamada, T. Nabeshima and H.-C. Kim
Affiliation:
Keywords: Gastrodia elata Bl, phencyclidine, schizophrenia, 5-HT1A receptors, chronic, devastating, anxiolytic, anti-depressant, anti-convulsant, anti-oxidant, anti-depressant effects
Abstract: It has been demonstrated that 5-HT1A receptors play an important role in the pathophysiology of schizophrenia. Because Gastrodia elata Bl (GE) modulates the serotonergic system, we examined whether GE could affect phencyclidine (PCP)-induced abnormal behavior in mice. Repeated treatment with PCP increased immobility time, while it decreased social interaction time and recognition memory. PCP-induced abnormal behaviors were significantly attenuated by GE, and these effects were comparable to those of 8-OH-DPAT, a 5-HT1A receptor agonist. Furthermore, GE-mediated effects were counteracted by WAY 100635, a 5-HT1A receptor antagonist. Our results suggest that the antipsychotic effects of GE are, at least in part, mediated via activation of 5-HT1A in mice.
Export Options
About this article
Cite this article as:
Shin E.-J., Kim J.-M., T. Nguyen X.-K., L. Nguyen T.-T., Y. Lee S., Jung J.-H., J. Kim M., K. Whang W., Yamada K., Nabeshima T. and Kim H.-C., Effects of Gastrodia Elata Bl on Phencyclidine-Induced Schizophrenia-Like Psychosis in Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017263
DOI https://dx.doi.org/10.2174/157015911795017263 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Nuclear Molecular Imaging of Protein Brain Receptors in Chronic Pain
Current Protein & Peptide Science Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Stress-related Risk Factors for the Maintenance of Major Depression in Adolescent Girls
Adolescent Psychiatry Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry Medicinal Plants and Natural Products: More Effective and Safer Pharmacological Treatment for the Management of Obesity
Current Drug Metabolism The Follow-Up of Dietary Treatment of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Natural or Plant Products for the Treatment of Neurological Disorders: Current Knowledge
Current Drug Metabolism Safety Assessment and Potential Risks of the Glucagon Stimulation Test in the Diagnosis of Secondary Adrenal Insufficiency
Current Drug Safety PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Gadolinium-based Imaging Contrast Agents
Current Medical Imaging Pain Alleviation in Anti-Inflammatory and Anti-Allergic Conditions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders
Current Pharmaceutical Design